ATR 1072 for Cardiomyopathy
What You Need to Know Before You Apply
What is the purpose of this trial?
ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug. Researchers will also assess how ATR 1072 affects PRKAG2 activity and measures of heart disease.
Are You a Good Fit for This Trial?
This trial is for adults aged 18 to 65 who have PRKAG2 Syndrome confirmed by genetic testing and show symptoms of the condition. Participants must be able and willing to follow study procedures, including a heart tissue biopsy.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- ATR 1072
Trial Overview
The study is testing ATR 1072, an experimental drug, in people with PRKAG2 Syndrome. It aims to see how safe the drug is, how the body handles it, and its effects on heart disease related to this syndrome.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Approximately 25 participants enrolled at the recommended phase 2 dose determined in Part A. ATR 1072 administered IV Q6W to further evaluate safety, PK, and pharmacodynamics.
Three sequential ascending dose cohorts (Dose Level 1, Dose Level 2 and Dose Level 3) with approximately 4 evaluable participants per cohort. ATR 1072 administered intravenously (IV) every 6 weeks (Q6W) for up to 8 doses (48-week treatment period).
Find a Clinic Near You
Who Is Running the Clinical Trial?
Atrium Therapeutics
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.